Bcl2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical responsiveness - reply
1998

Bcl-2 and Bax Proteins in Chronic Lymphocytic Leukaemia

publication Evidence: moderate

Author Information

Author(s): P Bentley, C Pepper, T Hoy

Primary Institution: Llandough Hospital

Hypothesis

The ratio of Bcl-2 to Bax proteins may determine susceptibility to apoptosis in chronic lymphocytic leukaemia cells.

Conclusion

Bcl-2 and Bax protein levels are significantly different in cells that resist apoptosis compared to those that do not.

Supporting Evidence

  • Bcl-2 and Bax protein levels differ significantly in apoptosis-resistant cells.
  • The study used Annexin V to measure apoptosis after drug treatment.

Takeaway

This study found that the balance of two proteins, Bcl-2 and Bax, helps decide if cancer cells live or die when treated with drugs.

Methodology

The study used triple-colour analysis to quantify Bcl-2 and Bax proteins in B-lymphocyte populations and measured apoptosis using Annexin V.

Limitations

The study did not differentiate between viable and non-viable cells in the analysis.

Statistical Information

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication